Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis

CONCLUSION: In our study, no difference was seen between the L/R combination and the SOC arm in terms of “progression to more severe state,” “mortality,” and virological cure on days 7–10;” however, some benefits in terms of “duration of hospital stay” and “time to virological cure” were seen. No significant difference in efficacy was seen when L/R was compared to arbidol and HCQ monotherapy. Except for the occurrence of diarrhea, which was higher in the L/R group, safety profile of L/R is comparable to SOC. Compared to L/R combination, CQ, L/R + arbidol, L/R + IFN-α, and L/R + IFN-1β showed better efficacy, but the external validity of these findings is limited by limited number of studies (1 study each).

Source: Indian Journal of Pharmacology - October 14, 2020 Category: Drugs & Pharmacology Authors: Anusuya Bhattacharyya Subodh Kumar Phulen Sarma Hardeep Kaur Manisha Prajapat Nishant Shekhar Seema Bansal Pramod Avti Mythili Hazarika Saurabh Sharma Dhruv Mahendru Ajay Prakash Bikash Medhi Source Type: research